Business Insights have teamed up with IMS Health to bring you, The Vaccines Market Outlook: Market analysis of future growth and leading players by sector. This unique report provides unrivalled analysis of changing market conditions and strategic future outlook using the gold standard IMS Health sales data, and also includes company reported sales data allowing you to spot any discrepancies between the two sets of data. Refresh your vaccines strategy with unrivalled analysis
The Vaccines Market Outlook: Market analysis of future growth and leading players by sector provides a detailed analysis of the vaccines market in the US and the five major European markets. The market for vaccines is broken down by population (pediatric and adult) and also by disease area. A comprehensive competitive overview is provided with an examination of key brands together with profiles of the leading players in this market.
This new report also reviews some of the most promising products in development, highlighting those expected to drive market growth in the future and in some cases become the first vaccine to market for a disease. Adult and travel vaccine segments are likely to drive growth in the future, use this latest vaccines report to discover the latest products which are set to transform this market.
Table of Contents
Executive summary
- Introduction to vaccines & vaccine-preventable diseases
- Vaccines market analysis
- Pediatric vaccines
- Adult vaccines
- Key players in the vaccines market
- Sources and limitations of vaccine sales data
Chapter 1 Introduction to vaccines &
- vaccine-preventable diseases
- Summary
- Introduction
- History of vaccines
- Vaccines and the immune system
- The immune system
- Immunity by vaccination
- Types of vaccines
- Problems with vaccine development
- DNA vaccines
- Vaccine-preventable diseases
- Measles
- Mumps
- Rubella
- Diphtheria
- Tetanus
- Pertussis
- Meningitis (pneumococcus, meningococcus and Hib)
- Varicella
- Hepatitis B
- Influenza
- Typhoid
- Rabies
Chapter 2 Vaccines market analysis
- Summary
- Introduction
- Vaccines as part of the infectious diseases market
- Vaccine market segments
- Leading vaccine brands
- Key players in the vaccines market
- Future growth drivers
Chapter 3 Pediatric vaccines
- Summary
- Introduction
- Pediatric immunization schedule
- Government recommendations
- Immunization funding
- US
- Europe
- Measles/Mumps/Rubella (MMR) vaccines
- Brand market share and sales
- Brand analysis
- MMR II
- Priorix
- Diphtheria/Tetanus/Pertussis (DTP) vaccines
- Brand market share and sales
- Brand analysis
- Infanrix & Infanrix HeXa
- Pediarix
- Hexavac & Pentacel
- Pneumococcal vaccines
- Brand market share and sales
- Brand analysis
- Prevnar
- Pneumovax 23
- Meningococcal vaccines
- Brand market share and sales
- Other pediatric vaccines
- Brand market share and sales
- Brand analysis
- Varivax
- Comvax
Chapter 4 Adult vaccines
- Summary
- Introduction
- Adult vaccine population
- Adolescent vaccination
- Elderly vaccination
- Traveler vaccination
- Hepatitis vaccines
- Brand market share and sales
- Brand analysis
- Engerix-B
- Recombivax HB
- Twinrix
- Havrix
- Influenza vaccines
- Brand market share and sales
- Brand analysis
- Fluzone
- Fluvirin
- FluMist
- Other adult vaccines
- Brand market share and sales
Chapter 5 Key players in the vaccine market
- Summary
- Introduction
- Merck & Co.
- Therapeutic focus
- Marketed vaccines portfolio
- R&D pipeline
- ProQuad
- HPV (human papilloma-virus) vaccine
- Zoster vaccine
- Rotateq
- Wyeth
- Therapeutic focus
- Marketed vaccines portfolio
- R&D pipeline
- GSK
- Therapeutic focus
- Marketed vaccines portfolio
- R&D pipeline
- Boostrix
- Priorix-Tetra
- Rotarix
- Conjugated meningitis A/C vaccine
- Cervarix
- Streptorix
- Simplirix
- Sanofi-Aventis
- Therapeutic focus
- Marketed vaccines portfolio
- R&D pipeline
- Menactra
- Adacel
- Chiron
- Therapeutic focus
- Marketed vaccines portfolio
- R&D pipeline
- MeNZB
- ACYW meningococcal vaccine
- Index
List of Figures
- Figure 1.1: Timeline of vaccine development
- Figure 2.2: Comparison of US/5EU IMS sales figures and global company-reported sales figures, 2003
- Figure 3.3: Pediatric vaccination schedule for the US and 5 major European markets, 2004
- Figure 3.4: Percentage of target population vaccinated the US, 5EU and global, 2003
- Figure 3.5: Pediatric target population, 2005
- Figure 3.6: MMR II SWOT analysis
- Figure 3.7: Priorix SWOT analysis
- Figure 3.8: Infanrix & Infanrix HeXa SWOT analysis
- Figure 3.9: Pediarix SWOT analysis
- Figure 3.10: Hexavac & Pentacel SWOT analysis
- Figure 3.11: Prevnar SWOT analysis
- Figure 3.12: Pneumovax 23 SWOT analysis
- Figure 3.13: Varivax SWOT analysis
- Figure 3.14: Comvax SWOT analysis
- Figure 4.15: Adolescent population in the US and 5 major European markets, 2005
- Figure 4.16: Elderly population in the US and 5 major European markets, 2005
- Figure 4.17: Number of deaths from influenza and pneumonia in the US, 1995-2002
- Figure 4.18: Engerix-B SWOT analysis
- Figure 4.19: Recombivax HB SWOT analysis
- Figure 4.20: Twinrix SWOT analysis
- Figure 4.21: Havrix SWOT analysis
- Figure 4.22: Fluzone SWOT analysis
- Figure 4.23: Fluvirin SWOT analysis
- Figure 4.24: FluMist SWOT analysis
- Figure 5.25: Comparison of US/5EU IMS sales figures and global company-reported sales figures, 2003
- Figure 5.26: Merck & Co s global therapeutic focus, 2003 & 2010
- Figure 5.27: Wyeth s global therapeutic focus, 2003 & 2010
- Figure 5.28: GSK s global therapeutic focus, 2003 & 2010
- Figure 5.29: Sanofi-Aventis global therapeutic focus, 2003 & 2010
- Figure 5.30: Chiron s global therapeutic focus, 2003 & 2010
List of Tables
- Table 2.1: Share of vaccines segment in anti-infectives market, US/Europe, 2002-2003
- Table 2.2: Sales of vaccine products by indication and country ($m), 2002-03
- Table 2.3: Top 10 vaccines in US/Europe by sales ($m), 2002-03
- Table 3.4: US/European sales of MMR vaccines ($m), 2002-03
- Table 3.5: US/European sales of combination vaccines with a tetanus component ($m), 2002-
- Table 3.6: US/European sales of pneumococcal vaccines ($m), 2002-03
- Table 3.7: US/European sales of meningococcal vaccines ($m), 2002-03
- Table 3.8: US/European sales of other pediatric vaccines ($m), 2002-03
- Table 4.9: US/European sales of hepatitis vaccines ($m), 2002-03
- Table 4.10: US/European sales of influenza vaccines ($m), 2002-03
- Table 4.11: US/European sales of other adult vaccines ($m), 2002-03
- Table 5.12: Merck s vaccines R&D pipeline and global sales forecasts, 2007 & 2010
- Table 5.13: Global sales of Wyeth s marketed vaccines portfolio ($m), 2002-03
- Table 5.14: Wyeth s vaccines R&D pipeline and global sales forecasts, 2007 & 2010
- Table 5.15: Global sales of GSK s marketed vaccines portfolio ($m), 2002-03
- Table 5.16: GSK s vaccines R&D pipeline and global sales forecasts, 2007 & 2010
- Table 5.17: Global sales of Sanofi-Aventis marketed vaccines portfolio ($m), 2002-03
- Table 5.18: Sanofi-Aventis vaccines R&D pipeline and global sales forecasts, 2007 & 2010
- Table 5.19: Sales of Chiron s marketed vaccines portfolio ($m), 2002-03
- Table 5.20: Chiron s vaccines R&D pipeline and global sales forecasts, 2007 & 2010
医薬品
その他のカテゴリ
FAQ